Extending the reach of gene therapies means hurdling not just scientific barriers but prices, too

While Covid-19 struck a blow to a vast number of clinical trials around the world, the pandemic may turn out to be a boon for bringing gene therapies to more people in the coming years.

“Who would have predicted three years ago that we’d now be having billions of doses manufactured of mRNA packaged in a lipid nanoparticle?” Sekar Kathiresan, CEO of Verve Therapeutics said Tuesday during the STAT Breakthrough Science Summit

Read the rest…